Evaluating the impact of SDHAF3 p.F53L genetic variant on clinically significant QTc prolongation in patients prescribed high-risk medications: a retrospective pharmacogenetic study.

Abstract excerpt

Drug-induced QT prolongation (diQTP) can lead to rare, but potentially fatal adverse effects of many medications, yet individual susceptibility varies due to both clinical and genetic factors. SDHAF3 p.F53L (rs62624461) is a genetic variant that plays a role in mitochondrial function and was previously associated with diQTP in one small prior study. Therefore, the objective of this retrospective pharmacogenetic...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aged